Catalent (NYSE:CTLT) Analyst Rating Consensus

Catalent (NYSE:CTLT) has received a short term rating of strong sell from experts at Zacks with a rank of 5. The stock has been rated an average of 2.33 by 9 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 6 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. William Blair downgrades their rating on the shares of Catalent (NYSE:CTLT). The current rating of the shares is Market Perform. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on May 5, 2016.

Catalent (NYSE:CTLT) should head towards $27.9 per share according to 5 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $25 per share. The higher price estimate target is at $31 according to the Analysts.

Catalent (NYSE:CTLT) rose 0.97% or 0.22 points on Tuesday and made its way into the gainers of the day. After trading began at $23.41 the stock was seen hitting $23.41 as a peak level and $22.53 as the lowest level. The stock ended up at $22.86. The daily volume was measured at 1,815,405 shares. The 52-week high of the share price is $34.415 and the 52-week low is $18.92. The company has a market cap of $2,850 million.

Shares of Catalent, Inc. appreciated by 1.78% during the last five trading days but lost 20.21% on a 4-week basis. Catalent, Inc. has dropped 14.61% during the last 3-month period . Year-to-Date the stock performance stands at -8.67%.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.